Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Predictive Oncology ( (POAI) ) has provided an announcement.
Predictive Oncology has entered into a Stock Exchange Purchase Agreement (SEPA) with an accredited investor, allowing the issuance and sale of shares of Common Stock. This transaction is conducted under the exemptions from registration requirements of the Securities Act, potentially impacting the company’s financial operations and investor relations.
The most recent analyst rating on (POAI) stock is a Buy with a $3.00 price target. To see the full list of analyst forecasts on Predictive Oncology stock, see the POAI Stock Forecast page.
Spark’s Take on POAI Stock
According to Spark, TipRanks’ AI Analyst, POAI is a Neutral.
The overall stock score is heavily impacted by poor financial performance and valuation metrics. The technical analysis also indicates bearish momentum. Regulatory challenges and the potential for Nasdaq delisting exacerbate the company’s risk profile.
To see Spark’s full report on POAI stock, click here.
More about Predictive Oncology
Average Trading Volume: 153,966
Technical Sentiment Signal: Strong Sell
Current Market Cap: $7.59M
For detailed information about POAI stock, go to TipRanks’ Stock Analysis page.